Loading data for ACAD — first visit, this takes a few seconds.
ACADIA Pharmaceuticals Inc. (ACAD)
NasdaqGS: ACAD
· 即時價格 · USD
28.02
+0.16 (0.57%)
收盤價： Sep 04, 2026, 3:59 PM
股價、關鍵數字和最新消息，都在這一頁。
ACADIA Pharmaceuticals Inc.（ACAD）股價、分析與資料
0.57% (1D)
| 買價 | 23.87 |
| 市值 | 4.83B |
| 營收 (ttm) | 1.14B |
| 淨利（ttm） | 380M |
| 0.86 | |
| 2.23 | |
| 12.57 | |
| 31.48 | |
| P/B (ttm) | 3.69 |
| P/S (ttm) | 4.21 |
| 財報日期 | Nov 4, 2026 |
| 賣價 | 31.79 |
| 成交量 | 1,682,950 |
| 20 日平均成交量 | 1,644,760 |
| 開盤價 | 27.77 |
| 前收盤價 | 27.86 |
| 當日區間 | 27.65 - 28.19 |
| 52 週範圍 | 19.69 - 30.96 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like gr...
完整的公司簡介財報驚奇
ACADIA Pharmaceuticals 已於 Aug 4, 2026 公布季度財報：
- 營收為 $307.96M 低於預期 $0, 年增 16.40% 成長.
- 每股盈餘為 0.18 超出預期 0.14, 年增 12.50% 成長.
第 1 頁，共 2 頁